FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024251653> ?p ?o ?g. }

• W2024251653 endingPage "1872" @default.
• W2024251653 startingPage "1871" @default.
• W2024251653 abstract "Sir,The article of Nakajima et al (2003) in the Journal addresses a problem of major public health importance, concluding that screening programme with immunochemical faecal occult blood test (FOBT) can be effective for prevention of advanced colorectal cancer. However, the screening method applied in their case–control study (i.e. the immunochemical haemagglutination method described by Saito et al (1995) may direct the attention to the rather controversial area of which is the optimal screening tool, if any, for early detection of colorectal cancer and its precursors.Recently, the scientific and clinical evidences for the use of the available colorectal cancer-screening tests were critically assessed (Walsh and Terdiman, 2003a, 2003b). Supported by a large body of direct and indirect evidence, those review articles concluded recommending that all asymptomatic men and women over 50 years of age and older should undergo screening; however, it stated, ‘at present, the available evidence does not support choosing any test over the others’. In the same time, after having reviewed the available evidence, a special advisory group appointed by the American Cancer Society highlighted immunological stool testing as the only exception from its general conclusion that this time there is insufficient evidence to recommend the other emerging technologies for routine colorectal cancer screening (Levin et al, 2003).Since the effectiveness of FOBT has been established by randomised controlled trials (Mandel et al, 1993; Mendel et al, 1999; Kronborg et al, 1996; Hardcastle et al, 1996), several tests based on peroxidase activity and guaiac-type reagents for colour reaction are most widely used on a public health scale, being noninvasive, simple and cheap methods, However, these reagents are not human-specific, because they may give positive reaction even with the peroxidase of several food stuffs, both of plant and animal origin (Cole and Young, 1999). These shortcomings result in an unacceptably high false positive rate.To eliminate these shortcomings, a number of combined methods consisting of a guaiac test and an immunochemical test have been developed. In addition to the increased specificity, the immunochemical FOBTs have the advantage of not requiring dietary or drug restrictions, therefore are more patient-friendly, and more suitable for mass application. In recent years, several such immunological techniques have developed (Otto and Eckhardt, 2000).However, several problems may reduce the efficiency of these methods (St John et al, 1993; Otto and Eckhardt, 2000). Most of these immunological techniques are usually limited to the demonstration of haemoglobin in the faeces. For example, depending on the site of bleeding, a certain degradation of haemoglobin may take place, or, faecal haemoglobin may become irreversibly bound to special components of the faeces. To eliminate these potential sources of error, some investigators have suggested the demonstration of additional proteins, more stable in the faeces than haemoglobin, as possible new indicators of intestinal bleeding.We ourselves have developed a combined electrophoretic–immunoprecipitation technique of high sensitivity (2 μg ml−1), suitable for simultaneous demonstration of two blood proteins, that is, haemoglobin and albumin, in the faecal sample (Otto and Nemeth, 1993). The technique is simple, inexpensive and suitable for the reliable detection of occult blood. The parallel demonstration of the two proteins significantly enhanced the detectability of symptomless colorectal cancer (Otto and Nemet, 1996). Furthermore, using immune sera raised against native haemoglobin and its fragments, as a differential diagnostic method, our technique is suitable for parallel demonstration of haemoglobin and its fragments; in this way, the origin of the bleeding can be localised (Otto et al, 1995).The modified two-phase (guaiac-type and immunochemical) faecal occult blood test (FECA-TEST) was used (without diet) as a screening tool in a pilot population-screening project for early detection of colorectal cancer. The project was carried out in 1997–1998 in a well-defined administrative area of the Capital, Budapest, Hungary (where – like in many other developed countries – colorectal cancer is the second leading cause of cancer death; therefore, screening for colorectal cancer is a major public health concern) with support from the World Bank ‘Close the gap’ public health programme. The purpose of the project was to demonstrate the feasibility and validity of the test is screening context, in addition to social acceptance and impact on early cure.In total, 21 945 persons of the target population received the sample collecting containers, distributed by the family physicians, and 6805 persons had returned it, thus the compliance rate was 31%. A total of 292 samples were technically unsatisfactory. The mean age of those tested was 64 years (49–86); 6513 samples were analysed at the Central Clinical Laboratory, National Institute of Oncology (NIO), Budapest. The very sensitive colour reaction was positive in 1892 cases (29% of all tested); in the second phase, the immunochemical Hgb and Alb reactions were positive (5.8% of all tests performed). The test-positive cases were referred for colonoscopic assessment to the NIO. Colonoscopy was performed on 243 persons (65% of those referred; the rest was lost for the follow-up). Colorectal cancer was detected and histologically confirmed in 12 cases (5% of all test positives); six out of 12 cancer cases proved to be in early stage (Dukes A). In additional 59 cases (20%), adenomatous polyps were found. In the 2-year follow-up period, seven cancer cases were diagnosed among those test-positive cases who rejected the endoscopic assessment. The parallel demonstration of the two proteins significantly enhanced the detectability of colorectal cancer.We are convinced that, at present, regular screening of population at average risk, using the combined immunological FOBT as screening tool, is the most promising way of reducing the colorectal cancer burden, one of the leading causes of cancer death in most of the developed countries worldwide." @default.
• W2024251653 created "2016-06-24" @default.
• W2024251653 creator A5012667699 @default.
• W2024251653 creator A5086450638 @default.
• W2024251653 date "2004-04-13" @default.
• W2024251653 modified "2023-10-17" @default.
• W2024251653 title "Screening for colorectal cancer with immunological FOBT" @default.
• W2024251653 cites W1579440956 @default.
• W2024251653 cites W1662237809 @default.
• W2024251653 cites W1966735728 @default.
• W2024251653 cites W1999988148 @default.
• W2024251653 cites W2007537740 @default.
• W2024251653 cites W2017130485 @default.
• W2024251653 cites W2019893869 @default.
• W2024251653 cites W2046686567 @default.
• W2024251653 cites W2054861910 @default.
• W2024251653 cites W2062369431 @default.
• W2024251653 cites W2079707364 @default.
• W2024251653 cites W2118835794 @default.
• W2024251653 cites W2134997723 @default.
• W2024251653 cites W2145602937 @default.
• W2024251653 doi "https://doi.org/10.1038/sj.bjc.6601798" @default.
• W2024251653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2409729" @default.
• W2024251653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15150617" @default.
• W2024251653 hasPublicationYear "2004" @default.
• W2024251653 type Work @default.
• W2024251653 sameAs 2024251653 @default.
• W2024251653 citedByCount "10" @default.
• W2024251653 countsByYear W20242516532012 @default.
• W2024251653 countsByYear W20242516532018 @default.
• W2024251653 crossrefType "journal-article" @default.
• W2024251653 hasAuthorship W2024251653A5012667699 @default.
• W2024251653 hasAuthorship W2024251653A5086450638 @default.
• W2024251653 hasBestOaLocation W20242516531 @default.
• W2024251653 hasConcept C121608353 @default.
• W2024251653 hasConcept C126322002 @default.
• W2024251653 hasConcept C143998085 @default.
• W2024251653 hasConcept C526805850 @default.
• W2024251653 hasConcept C71924100 @default.
• W2024251653 hasConceptScore W2024251653C121608353 @default.
• W2024251653 hasConceptScore W2024251653C126322002 @default.
• W2024251653 hasConceptScore W2024251653C143998085 @default.
• W2024251653 hasConceptScore W2024251653C526805850 @default.
• W2024251653 hasConceptScore W2024251653C71924100 @default.
• W2024251653 hasIssue "9" @default.
• W2024251653 hasLocation W20242516531 @default.
• W2024251653 hasLocation W20242516532 @default.
• W2024251653 hasLocation W20242516533 @default.
• W2024251653 hasLocation W20242516534 @default.
• W2024251653 hasOpenAccess W2024251653 @default.
• W2024251653 hasPrimaryLocation W20242516531 @default.
• W2024251653 hasRelatedWork W2075214100 @default.
• W2024251653 hasRelatedWork W2364051953 @default.
• W2024251653 hasRelatedWork W2365364931 @default.
• W2024251653 hasRelatedWork W2381416288 @default.
• W2024251653 hasRelatedWork W2388808113 @default.
• W2024251653 hasRelatedWork W2392730113 @default.
• W2024251653 hasRelatedWork W2418638721 @default.
• W2024251653 hasRelatedWork W2949011490 @default.
• W2024251653 hasRelatedWork W3004259476 @default.
• W2024251653 hasRelatedWork W3039284339 @default.
• W2024251653 hasVolume "90" @default.
• W2024251653 isParatext "false" @default.
• W2024251653 isRetracted "false" @default.
• W2024251653 magId "2024251653" @default.
• W2024251653 workType "article" @default.